The clinical pharmacology of the medical treatment for overactive bladder in adults |
| |
| Authors: | Hadi Mostafaei Hanieh Salehi-Pourmehr Florian Janisch Keiichiro Mori Fahad Quhal |
| |
| Affiliation: | 1. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna , Vienna, Austria;2. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences , Tabriz, Iran;3. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences , Tabriz, Iran;4. Student Research Committee, Tabriz University of Medical Sciences , Tabriz, Iran;5. Department of Urology, Medical University of Hamburg , Hamburg, Germany;6. Department of Urology, The Jikei University School of Medicine , Tokyo, Japan;7. King Fahad Specialist Hospital-Dammam , Saudi Arabia !["ORCID]("//:0" "\"ORCID") https://orcid.org/0000-0002-8163-6953 |
| |
| Abstract: | ABSTRACT Introduction Overactive bladder is a prevalent symptom complex that affects the patient’s quality of life. Any disruption between the neuronal micturition pathway can lead to bladder overactivity. Neurogenic causes, myogenic causes, aging, bladder outlet obstruction, sex, and psychological factors are some of the factors contributing to bladder overactivity. The complaint of any symptoms of OAB, which is highly prevalent and affects overall QOL, often needs therapeutic interventions. When conservative therapy methods fail, the addition of medications is recommended. The most commonly used agents for the treatment of OAB are antimuscarinic drugs. New classes of drugs, such as beta-3 agonists, have enriched our pharmacologic armamentarium. |
| |
| Keywords: | Pharmacotherapy overactive bladder medical treatment antimuscarinics β-adrenoceptor agonists botulinum toxin-A |
|
|
!["ORCID]({"type":"image","src":"/templates/jsp/images/orcid.png"} "\"ORCID")
https://orcid.org/0000-0002-8163-6953